- Home
- CAPT vs KLRS Comparison
CAPT vs KLRS Comparison
Compare CAPT & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- KLRS
- Stock Information
- Founded
- CAPT 2005
- KLRS 2019
- Country
- CAPT South Korea
- KLRS United States
- Employees
- CAPT N/A
- KLRS N/A
- Industry
- CAPT Blank Checks
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CAPT Finance
- KLRS Health Care
- Exchange
- CAPT Nasdaq
- KLRS Nasdaq
- Market Cap
- CAPT 41.1M
- KLRS 46.0M
- IPO Year
- CAPT N/A
- KLRS N/A
- Fundamental
- Price
- CAPT $1.06
- KLRS $2.57
- Analyst Decision
- CAPT
- KLRS Buy
- Analyst Count
- CAPT 0
- KLRS 1
- Target Price
- CAPT N/A
- KLRS N/A
- AVG Volume (30 Days)
- CAPT 161.0K
- KLRS 47.9K
- Earning Date
- CAPT 01-01-0001
- KLRS 08-13-2025
- Dividend Yield
- CAPT N/A
- KLRS N/A
- EPS Growth
- CAPT N/A
- KLRS N/A
- EPS
- CAPT N/A
- KLRS N/A
- Revenue
- CAPT $17,389,944.00
- KLRS N/A
- Revenue This Year
- CAPT N/A
- KLRS N/A
- Revenue Next Year
- CAPT N/A
- KLRS N/A
- P/E Ratio
- CAPT N/A
- KLRS N/A
- Revenue Growth
- CAPT 84.70
- KLRS N/A
- 52 Week Low
- CAPT $0.37
- KLRS $2.14
- 52 Week High
- CAPT $2.60
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- CAPT 39.31
- KLRS 49.87
- Support Level
- CAPT $1.13
- KLRS $2.37
- Resistance Level
- CAPT $1.30
- KLRS $2.58
- Average True Range (ATR)
- CAPT 0.07
- KLRS 0.17
- MACD
- CAPT -0.02
- KLRS 0.01
- Stochastic Oscillator
- CAPT 10.34
- KLRS 65.85
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.